The DOI matches its Crossref record.
Hypoglycemia in the Diabetes Control and Complications Trial
Abstract
A total of 1,441 patients with IDDM were randomly assigned to receive either intensive (n = 711) or conventional (n = 730) diabetes therapy in the Diabetes Control and Complications Trial (DCCT). The patients were followed for an average of 6.5 years. Subjects were instructed to report all episodes of suspected severe hypoglycemia to their health care team. In addition, at quarterly follow-up visits, each subject was asked about the occurrence of severe hypoglycemia. There were 3,788 episodes of severe hypoglycemia (requiring assistance); 1,027 of these episodes were associated with coma and/or seizure. A total of 65% percent of patients in the intensive group vs. 35% of patients in the conventional group had at least one episode of severe hypoglycemia by the study end; the overall rates of severe hypoglycemia were 61.2 per 100 patient-years vs. 18.7 per 100 patient-years in the intensive and conventional treatment groups, respectively, with a relative risk (RR) of 3.28. The relative risk for coma and/or seizure was 3.02 for intensive therapy. The increased risk with intensive treatment persisted over each of the 9 years of follow-up in the DCCT and over the calendar years 1984–1993 during which the study was conducted. When baseline patient characteristics were examined for effects on the risk of severe hypoglycemia, the relative risk of hypoglycemia for intensive versus conventional treatment was ≥2 for all subgroups. Several subgroups defined by baseline characteristics, including males, adolescents, and subjects with no residual C-peptide or with a prior history of hypoglycemia, had a particularly high risk of severe hypoglycemia in both treatment groups. Analyses of the cumulative incidence of successive episodes indicated that intensive treatment was also associated with an increased risk of multiple episodes within the same patient (e.g., 22% experienced five or more episodes of severe hypoglycemia within the first 5 years of follow-up vs. 4% in the conventional group). Within both treatment groups, patients who experienced severe hypoglycemia were at increased risk of subsequent episodes. Approximately 30% of patients in each group experienced a second episode within the 4 months following the first episode of severe hypoglycemia. Within each treatment group, the number of prior episodes of hypoglycemia was the strongest predictor of the risk of future episodes, followed closely by the current HbA1c value. After adjustment for the current quarterly HbA1c level, intensive treatment was still associated with a significantly increased risk of hypoglycemia, indicating that the increased risk with intensive treatment is not completely explained by differences in HbA1c values.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trials have established that intensive glycemic therapy prevents or delays the microvascular complications-retinopathy, nephropathy, and neuropathy-of diabetes (122, 123, 131, 144, 145), albeit at the expense of an increased frequency of hypoglycemia (117, 118, 122, 123, 132, 133, 144, 145).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [133]
In the citing paper
“A glucose of <70 mg/dL (3.9 mmol/L) is the classic threshold for hypoglycemia based on physiologic glucose regulation and neuroendocrine response in persons without DM.1197”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1197]
Citations
Cites
Still being checked.
Cited by
Items 701–779 of 779
Amiel, S. A. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch7
Managing Common Conditions Associated with Diabetes
Dunning, T. (2009) · Wiley eBooks · doi:10.1002/9781444320893.ch10
Does A1c Have to Change for Hypoglycemia Reduction?
Renard, É. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0164
Is Multiple Injection Therapy the Treatment of Choice in Type 1 Diabetes?
Janssen, M. M. J., & Heine, R. J. (2001) · Wiley eBooks · doi:10.1002/9780470757109.ch12
The Role of Glycemia in Diabetic Complications
Amiel, S. A. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0902
Perioperative care of the patient with diabetes mellitus
Hall, G., Hunter, J. M., & Cooper, M. S. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511750441.009
Insel(zell)-Transplantationen bei Typ-1-Diabetes-Patienten
Brendel, M. D., Ludwig, B., Eckhard, M., & Bretzel, R. G. (2010) · Der Diabetologe · doi:10.1007/s11428-010-0561-3
Aspectos clínicos y diagnósticos de la diabetes infantil
Bouhours‐Nouet, N., & Coutant, R. (2011) · EMC - Pediatría · doi:10.1016/s1245-1789(11)71180-5 · Cited by 2
BGAT, BINGO or BASH—What's in a name?
Everett, J., & Kerr, D. E. (2002) · Practical Diabetes · doi:10.1002/pdi.395
An Innovative Approach for Predicting Severe Hypoglycemia
Siminerio, L. M. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.1.18
Pharmacothérapie du diabète de type 1
McGibbon, A., Richardson, C., Hernandez, C. A., & Dornan, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.005 · Cited by 2
Bolli, G. B., & Porcellati, F. (2003) · L Endocrinologo · doi:10.1007/bf03344474
Contreras, I., & Vehí, J. (2015) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2015.10.170
Bandello, F. M., Parodi, M. B., Lanzetta, P., Loewenstein, A., Massin, P., & Menchini, F. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0118-6_6
Schoumacker-Ley, L., Duchesne, L., Cuny, T., Böhme, P., Benzirar, S., Fay, R., Ziegler, O., & Guerci, B. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30034-2
Verapamil is a potential therapy for hypoglycaemic brain injury
Hwang, J. J., & Sherwin, R. S. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0056-7
SGLT-Hemmer als therapeutische Option bei Patienten mit Typ 1 Diabetes mellitus
Sourij, C., Obermayer, A. M., & Sourij, H. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0050-7
Rouf, R. S. B., & Pathan, M. F. (2019) · Bangladesh Journal of Medicine · doi:10.3329/bjmed.v30i1.39920
Coventional Insulin versus Insulin Analogs
Gomber, A., & Gomber, A. (2019) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/jmgims.jmgims_5_19
Demographic Influences and Health Disparities
Mironovici, C., Kepper, M. M., Scribner, R. A., & Chalew, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-33286-0_13
Philippou, E. (2016) · CRC Press eBooks · doi:10.1201/9781315371764-12
Roy, S., Biswas, C., Bera, M., & Bhattacharya, G. (2020) · Clinical Diabetology · doi:10.5603/dk.2019.0027
Zennaki, A., NACEUR, M., Latroch, C., Aoui, A., GHARNOUTI, M., Taleb, N. O., BOUZIANE-NEDJADI, K., BOUDRAA, G., & TOUHAMI, M. (2018) · Journal de la faculté de médecine d Oran · doi:10.51782/jfmo.v2i2.66
Ryan, C. M. (2002) · Elsevier eBooks · doi:10.1016/b978-012532104-4/50102-5
Leptin, Diabetes, and the Obesity—A Corelation
Batta, A. K. (2020) · Scholars International Journal of Biochemistry · doi:10.36348/sijb.2020.v03i02.005
Diabetes Control, Long-Term Complications, and Large Vessel Disease
Nathan, D. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00051-4
Frenzke, H., Varnhorn, A., Schulze, H., Kahle, M., & Nauck, M. A. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1190-3614
Hypoglycemia Detection Based on ear-EEGPreprint
Cabrera, A. F., Kappel, S. L., Remvig, L. S., Toft, H. O., Madsen, R. E., Kildmose, P., & Rank, M. L. (2020) · Research Square · doi:10.21203/rs.3.rs-122971/v1
Choksi, I., Mencher, S., & Patel, A. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-64133-7_10
Dunning, M. P. T. (2009) · Wiley eBooks · doi:10.1002/9781444320893.ch6
Lachin, J. M. (2010) · Wiley series in probability and statistics · doi:10.1002/9780470907412.refs
Romeo, G. R., Silva, P. S., & Cavallerano, J. D. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_294-1
Lamos, E. M., Younk, L. M., & Davis, S. N. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch31
(2006) · Springer eBooks · doi:10.1007/3-540-26602-x_14
Islet and Pancreas Transplantation
Mineo, D., Ciancio, G., Burke, G. W., Alejandro, R., & Ricordi, C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-366-4_2 · Cited by 1
Weißenborn, K. (2017) · Springer eBooks · doi:10.1007/978-3-662-44768-0_112-1
Lachin, J. M. (2000) · Wiley series in probability and statistics · doi:10.1002/9780470317051.refs
Mezitis, N. H. E., & Mezitis, S. G. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_39
Conget, I., Ávila, D., Giménez, M., Quirós, C., Salaverría, V., & Dueñas, B. (2016) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2016.02.008
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00894-5
Mesotten, D., & den Berghe, G. V. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1367-1.00018-5
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
Frier, B. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-850-8_6
Aspectos clínicos y diagnósticos de la diabetes infantil
Louvigné, M., Decrequy, A., Donzeau, A., Bouhours‐Nouet, N., & Coutant, R. (2018) · EMC - Pediatría · doi:10.1016/s1245-1789(17)88072-0 · Cited by 1
References, Bibliography & Further Reading
(2012) · Elsevier eBooks · doi:10.1016/b978-0-443-10081-9.00007-5
Weißenborn, K. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-60676-6_112
Diabetes Technology and Treatment in the Paediatric Age Group
Shalitin, S., & Chase, H. P. (2012) · Wiley eBooks · doi:10.1002/9781118321508.ch11
Risk factors for severe hypoglycaemia in the treatment of IDDM
&NA; (1997) · Reactions Weekly · doi:10.2165/00128415-199706410-00013
Clayton, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.007 · Cited by 5
Fetian, I. R., Maziukas, R., Pisarcikova, Z., Zechmann, S., Dolinar, M., Dolinar, S., & Villiger, L. (2022) · doi:10.36000//hbt.2022.05.001
Kröger, J. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00941-1
CLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide Secretion
Bolinder, J. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209740
Hypoglycaemia ??? a little glucose is a dangerous thing
&NA; (2005) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200521030-00004
Levy, M., & Thivolet, C. H. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.002
Self, W. H., & McNaughton, C. D. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-3548-2.00163-4
Ashraf, M., Sun, J. K., Silva, P. S., Cavallerano, J. D., & Aiello, L. P. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_15 · Cited by 1
Dezashibi, H. M., Farzad‐Mohajeri, S., Bandehpour, M., Shabani, A., & Kazemi, B. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3876
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
Prediction of Insulin-Dependent T2DM in Patients Using Machine Learning Model
Gowthami, S., Reddy, R., & Ahmed, M. R. (2024) · International Conference on Intelligent Data Communication Technologies and Internet of Things (IDCIoT) · doi:10.1109/idciot59759.2024.10467795
Modifiable self-management practices impact nocturnal and morning glycaemia in type 1 diabetes
Ahola, A. J., Parente, E. B., Harjutsalo, V., & Groop, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.007
Salman, R. I., & Al-Lami, F. (2024) · International Journal of Advanced Community Medicine · doi:10.33545/comed.2024.v7.i3b.330 · Cited by 1
Rationale for and Physiological Basis of Intensive Diabetes Management
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch01
The impact of antidiabetic medications on COVID-19 outcomes in diabetic patients: an overview
Zarei, M., Vaighan, N. S., Shiravand, S., Samani, S. M. V., Sheikholeslami, M. A., & Roudbari, Z. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.4.363
Bader, S., Ashfaq, A., Mussa, B. M., & Abusanana, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6563191/v1
Peacock, Z. S., & Pogrel, M. A. (2025) · Oral and Maxillofacial Surgery · doi:10.1002/9781119842958.ch1.2
Hypoglycemia Not Reverting with Sugar: The Unexplained Hypos
Bhat, S. (2025) · Springer eBooks · doi:10.1007/978-981-95-0636-1_62
Coustans, L., Collay, S., Metz, C., de Parscau, L., Bismuth, É., Ollivier, L., & Teissier, R. (2025) · Archives de Pédiatrie · doi:10.1016/j.arcped.2025.03.008
Sani, S. R., Taheri, H., Amirbeik, A., Dadkhah, P. A., Chichagi, F., Kalanimehr, A., Pakmehr, S., Shafagh, S.-G., Valipoor, R., Nakhaee, M., et al. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00577-9
Management of Acute and Recurrent Hypoglycaemia
McCrimmon, R. J. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch8
Bilal, A., Horton, W. B., Kovatchev, B. P., Casu, A., Pratley, R., Kanapka, L., & Beck, R. W. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261432166
Bolli, G. B., Home, P., Lepore, M., Riddle, M. C., Porcellati, F., Fanelli, C. G., Lucidi, P., Yki‐Järvinen, H., Becker, R. H. A., & Owens, D. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70751
Nutrition Therapy for Diabetic Gastroparesis
Hodgson, E. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch19
Eye Health Among Islet Cell Transplant Recipients With Long-duration Type 1 Diabetes
Kwon, H. J., McAuley, S. A., MacIsaac, R. J., Kay, T., & Ward, G. M. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001960
Bader, S., Ashfaq, A., Mussa, B. M., Alawadi, F., Bhamidimarri, P. M., Al-Abadla, Z., & Abusnana, S. (2026) · Acta Neurologica Scandinavica · doi:10.1155/ane/6400429
Ganji, M., Lobo, B. J., Fathi, A. E., Fabris, C., & Kovatchev, B. P. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261489629
Markmann, J., Oberholzer, J., Turgeon, N., Naji, A., Posselt, A., Ricordi, C., Shapiro, J., Kaufman, D., Hering, B., & Luo, X. (2020) · ImmPort · doi:10.21430/m33gz8ur05
Hypoglycemia: An Endocrine Emergency
Guettier, J., & Görden, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-177-6_7 · Cited by 1
Untitled work
Diabetes Canada Clinical Practice Guidelines Expert Committee (n.d.) · Diabetes Canada
Metadata
- Authors
- The Diabetes Control and Complications Trial Research Group
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Diabetes Control and Complications Trial Research Group
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-02-01
- Volume
- 46
- Issue
- 2
- Pages
- 271-286
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W4252271922
- Semantic Scholar
- 0b14f6e58470afda31b2a9daa1c3fb61be7dad5a
- Cited by
- 746
- References
- 0
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 23 · 2021: 21 · 2020: 30 · 2019: 34 · 2018: 41 · 2017: 36 · 2016: 36 · 2015: 47 · 2014: 45 · 2013: 36 · 2012: 33
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- severe hypoglycemia, type 1 diabetes, intensive insulin therapy, baseline characteristics, Diabetes Control and Complications Trial, hypoglycemia risk factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.